DAY 1

9:00 **Welcome and introduction by organizers and co-sponsors**

Nikola Biller-Andorno, Stéphanie Dagron *(Institute of Biomedical Ethics, University of Zurich)*

Thomas Heiniger (*State Councillor, Head of Department of Health, Canton Zurich)*

Rüdiger Krech (*Director, Dept. of Ethics, Equity, Trade and Human Rights, World Health Organization*)

Peter Suter (*President, Swiss Academy of Medical Sciences)*

Session I: COUNTRY MODELS: INSTITUTIONS, FUNCTIONS, APPROACHES – LESSONS LEARNED

9:30-11:00 UK: Kalipso Chalkidou *(Director, NICE International Programme)*

France: Anne d'Andon *(Head, Medicine Assessment Unit, Haute Autorité de Santé)*

Germany: Stefan Lange *(Deputy Director, IQWIG)*

Netherlands: Martin Buijsen *(Prof., Institute of Health Policy and Management, Erasmus University Rotterdam)*

11:00-11:30 Break

11:30-12:15 Sweden: Jan Liliemark *(Prof., Program Manager, SBU-Swedish Council on Health Technology Assessment)*

Switzerland: Max Baumann *(Prof., University of Zurich; Member of the Medical Board project team)*

12:15-13:00 Discussion: Key differences, learning from each other, transfer of knowledge

13:00-14:00 Lunch

Session II: CHALLENGES AHEAD

14:00-15:30 **Conceptual and methodological challenges**

Claudia Wild *(Priv. Doz., Director Ludwig-Boltzmann Institute for Health Technology Assessment, Vienna)*

Wija Oortwijn *(Principal Health Consultant at ECORYS)*

Jos Kleijnen *(Prof., Kleijnen Systematic Reviews Ltd., York)*

Lise Rochaix *(Prof., Haute Autorité de Santé, Chairwoman, Economic Evaluation and Public Health Committee*)

Alois Gratwohl (*Prof. emeritus, University of Basel)*

15:30-16:00 Break

16:00-17:30 **Legal challenges**

Stéphanie Dagron *(Senior Research Fellow, Institute of Biomedical Ethics, University of Zurich)*

Keith Syrett *(Reader in Public Law and Health Policy, School of Law, University of Bristol)*

Ethical challenges

Björn Hofmann *(Section for Medical Ethics, Faculty of Medicine, University of Oslo)*

Gert Jan van der Wilt *(Prof., Radboud University Medical Centre, Nijmegen)*

Georg Marckmann (*Prof., University of Tübingen)*

17:30 **COCKTAIL RECEPTION**
Welcome Address by Klaus Grätz *(Prof., Dean, Medical Faculty, University of Zurich)*

INAUGURATION CEREMONY: IBME as a WHO Collaborating Center for Bioethics

18:30-20:00 **KEYNOTE:** HTA and US health care reform

Alexander Capron *(Univ.Prof., Scott H. Bice Chair in Healthcare Law, Policy and Ethics, University of Southern California)*

DAY 2

Session III: CASE STUDIES

9:00-10:00 Case Study 1 – 4 (break-out groups)

10:00-10:30 Break

10:30-12:00 Plenary discussion of case studies

12:00-13:00 Lunch

Session IV: ELEMENTS FOR BEST PRACTICE

13:00-13:30 **WHO perspective**

Kees de Jonchère *(Regional Advisor Health Technology and Pharmaceuticals, WHO Regional Office for Europe)*

Andreas Reis *(Dept. of Ethics, Equity, Trade and Human Rights, WHO, Geneva)*

13:30-15:00 **Discussion:** How to avoid ethical pitfalls
Recommendations for practice

15:00-15:30 **Wrap-up**
Peter Suter, Nikola Biller-Andorno

Brief description

European health systems face common challenges in the form of finite health resources. Currently there are several national or regional institutions in charge of determining how resources should be spent. In France, Germany and the United Kingdom, for instance, institutions such as HAS, IQWIG and NICE have been entrusted with an appreciation of empirical data regarding the cost-effectiveness of pharmaceuticals and medical devices. The Swiss federal law on health insurance stipulates that all medical benefits and services have to be efficient, adequate and cost-effective. The Canton of Zurich started a pilot project in 2008 by entrusting a Medical Board with the task of developing a model for assessing efficiency and cost effectiveness of the therapeutic procedures that are eligible for insurance coverage. The implementation of a permanent institution is currently a matter of debate.

The goal of this workshop is to debate the conceptual, methodological, legal and ethical challenges for national agencies involved in health resource allocation decisions as well as to start identifying essential elements for best practice. It aims to inform the current developments in Switzerland as well as the broader discussion on such issues at the international level, with a focus on European countries.

Participants include representatives from the relevant national institutions from France, Germany, the UK, Sweden, Austria and the Netherlands; key stakeholders such as patients' organizations, practitioners, the pharmaceutical and insurance industries as well as scholars from the fields of ethics, law, health, economics and medicine.

Invited speakers will give a short presentation, followed by discussion and exchange.

Contact person:
Dr. Stéphanie Dagron, dagron@ethik.uzh.ch

Venue:
Careum 2 C-290 Pestalozzistr. 3/5, Zurich

Organized by:

University of Zurich[UZH] Institute of Biomedical Ethics

WHO Collaborating Centre for Bioethics

Collaborators and co-sponsors

Kanton Zürich Gesundheitsdirektion

University of Zurich[UZH] URPP Ethics

SAMS Swiss Academy of Medical Sciences

Institute of Biomedical Ethics
PhD Program in Biomedical Ethics
& Law/medical track

INTERNATIONAL WORKSHOP:

The role of health technology assessment agencies in national rationing policies: towards elements for best practice

&

INAUGURAL EVENT:

Designation of the Institute of Biomedical Ethics, University of Zurich, as a WHO Collaborating Centre for Bioethics

Zurich, 25-26 October 2010

University of Zurich[UZH]